25.09.2019 • News

BASF Sells Ultrafiltration Membranes to DuPont

BASF Sells Ultrafiltration Membranes to DuPont (c) BASF
BASF Sells Ultrafiltration Membranes to DuPont (c) BASF

BASF has agreed to sell its ultrafiltration membrane business to DuPont for an undisclosed sum. The deal includes the business’s international workforce, headquarters and production site in Greifenberg, Germany, and associated intellectual property.

It also includes BASF’s subsidiary inge GmbH, which manufactures the ultrafiltration membranes used in treating drinking water, process water, waste water and sea water. BASF acquired inge in August 2011 from its private investor owners.

Anup Kothari, president, Performance Chemicals, BASF, said synergies between inge and BASF are very limited and being part of a strategic buyer such as DuPont provides “strong value creation potential and will enable it to reach the next level of growth”.

The business strengthens DuPont’s portfolio of water purification and separation technologies, including ultrafiltration, reverse osmosis and ion exchange resins. “This technology in combination with inge’s expert team further broadens our portfolio and enhances our ability to design tailored, integrated solutions for drinking water, industrial and waste water treatment applications globally,” commented Rose Lee, president of DuPont Safety & Construction.

The transaction is anticipated to close by the end of 2019, pending approval by the relevant authorities.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read